Target
DNA polymerase
17 abstracts
Abstract
A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.Org: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hygeia Suzhou Yongding Hospital, National Regional Medical Center,
Abstract
Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4).Org: School of Public Health & Preventative Medicine, Monash University, Melbourne, Australia, Hospital Universitario Doctor Peset, Valencia, Spain, Hospital Virgen de las Nieves, Granada, Spain, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Australia, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea,
Abstract
FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Leukemia,
Abstract
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia (AML) treated on SWOG S1203.Org: University of Washington/Fred Hutchinson Cancer Center, University of Washington/Fred Hutchinson Cancer Center and SWOG Statistics and Data Management Center, Seattle, WA, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Duke Cancer Institute, Duke University Medical Center, Durham, NC,
Abstract
Outcomes of 3- versus 5-day administration schedule of consolidation cytarabine in adults with acute myeloid leukemia (AML).Org: University of Alabma at Birmingham, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Department of Pharmacy and Pharmacology,
Abstract
Predictors of early port infection in adult patients with acute myeloid leukemia.Org: University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Surgical Oncology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, The University of Alabama at Birmingham/O'Neal Comprehensive Cancer Center,
Abstract
First-in-human trial of tocilizumab in combination with a standard induction chemotherapy in newly diagnosed acute myeloid leukemia patients: The phase 1 TOCILAM study.Org: CHU de Nantes, Hôpital Hôtel-Dieu, Nantes, France, Service d'Hématologie Clinique - CHU Pontchaillou, Hotel Dieu - HME, Clinical Research Centre, Departmental Hospital Centre,
Abstract
Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.Org: University of Texas MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Stem Cell Transplantation & Cellular Therapy,
Abstract
Association of intensive chemotherapy with the rate of pathogenic driver mutation clearance in acute myeloid leukemia.Org: Ochsner Clinic Foundation, University of Queensland, Ochsner Health System,
Abstract
Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.Org: CicloMed, Tessa Pharmaceutics LLC, Notable Labs, CritiTech, Inc, The Gnomon Group,
Abstract
Social determinants of health as a primary driver in outcomes in acute myeloid leukemia: An urban academic center experience.Org: VCU Massey Cancer Center, VCU School of Medicine, VCU Department of Internal Medicine, VCU Department of Biostatistics,
Abstract
Outcomes of different therapies in acute myeloid leukemia patients with core-binding factor.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, First Affiliated Hospital of Wannan Medical College, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Hangzhou, Zhejiang, China,
Abstract
Predictors of survival outcomes in patients with MECOM EVI1 rearrangement aberrations in AML or MDS.Org: Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic Jacksonville, Division of Hematopathology, Mayo Clinic, Rochester, MN,
Abstract
Early death (ED) in elderly acute promyelocytic leukemia (APL) patients treated with lower induction doses of all-trans retinoic acid (ATRA).Org: Medical College of Georgia at Augusta University, Georgia Cancer Center at Augusta University, Augusta University Georgia Cancer Center,
Abstract
Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA,
Abstract
Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Identification of predictive, treatment-specific Charlson comorbidity score thresholds in acute myeloid leukemia.Org: VCU Massey Cancer Center, VCU School of Medicine, VCU Department of Internal Medicine, VCU Department of Biostatistics,